vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Ralliant Corp (RAL). Click either name above to swap in a different company.
Ralliant Corp is the larger business by last-quarter revenue ($529.1M vs $284.0M, roughly 1.9× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 7.5%, a 88.8% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -0.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
ACAD vs RAL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $529.1M |
| Net Profit | $273.6M | $39.9M |
| Gross Margin | 90.8% | 50.8% |
| Operating Margin | 6.1% | 9.8% |
| Net Margin | 96.3% | 7.5% |
| Revenue YoY | 9.4% | -0.5% |
| Net Profit YoY | 90.3% | -56.1% |
| EPS (diluted) | $1.61 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | — | ||
| Q3 25 | $278.6M | $529.1M | ||
| Q2 25 | $264.6M | $503.3M | ||
| Q1 25 | $244.3M | — | ||
| Q4 24 | $259.6M | — | ||
| Q3 24 | $250.4M | $531.7M | ||
| Q2 24 | $242.0M | $533.7M | ||
| Q1 24 | $205.8M | — |
| Q4 25 | $273.6M | — | ||
| Q3 25 | $71.8M | $39.9M | ||
| Q2 25 | $26.7M | $47.6M | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $32.8M | $90.9M | ||
| Q2 24 | $33.4M | $64.8M | ||
| Q1 24 | $16.6M | — |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | 50.8% | ||
| Q2 25 | 92.2% | 49.3% | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | 52.6% | ||
| Q2 24 | 92.5% | 51.5% | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | — | ||
| Q3 25 | 12.8% | 9.8% | ||
| Q2 25 | 12.2% | 11.7% | ||
| Q1 25 | 7.9% | — | ||
| Q4 24 | 59.1% | — | ||
| Q3 24 | 12.6% | 20.9% | ||
| Q2 24 | 12.6% | 19.7% | ||
| Q1 24 | 7.4% | — |
| Q4 25 | 96.3% | — | ||
| Q3 25 | 25.8% | 7.5% | ||
| Q2 25 | 10.1% | 9.5% | ||
| Q1 25 | 7.8% | — | ||
| Q4 24 | 55.4% | — | ||
| Q3 24 | 13.1% | 17.1% | ||
| Q2 24 | 13.8% | 12.1% | ||
| Q1 24 | 8.0% | — |
| Q4 25 | $1.61 | — | ||
| Q3 25 | $0.42 | $0.35 | ||
| Q2 25 | $0.16 | $0.42 | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | $0.81 | ||
| Q2 24 | $0.20 | $0.57 | ||
| Q1 24 | $0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $264.2M |
| Total DebtLower is stronger | — | $1.1B |
| Stockholders' EquityBook value | $1.2B | $3.0B |
| Total Assets | $1.6B | $5.3B |
| Debt / EquityLower = less leverage | — | 0.39× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | $264.2M | ||
| Q2 25 | $253.6M | $198.6M | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | — | ||
| Q1 24 | $204.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $917.3M | $3.0B | ||
| Q2 25 | $822.4M | $3.0B | ||
| Q1 25 | $765.2M | — | ||
| Q4 24 | $732.8M | — | ||
| Q3 24 | $577.2M | $4.0B | ||
| Q2 24 | $516.7M | $4.0B | ||
| Q1 24 | $464.0M | — |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.3B | $5.3B | ||
| Q2 25 | $1.2B | $5.2B | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $976.9M | — | ||
| Q2 24 | $914.1M | — | ||
| Q1 24 | $855.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $138.6M |
| Free Cash FlowOCF − Capex | — | $126.6M |
| FCF MarginFCF / Revenue | — | 23.9% |
| Capex IntensityCapex / Revenue | — | 2.3% |
| Cash ConversionOCF / Net Profit | -0.18× | 3.47× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | — | ||
| Q3 25 | $74.3M | $138.6M | ||
| Q2 25 | $64.0M | — | ||
| Q1 25 | $20.3M | — | ||
| Q4 24 | $40.4M | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | $25.0M | — | ||
| Q1 24 | $29.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | $126.6M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | 23.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | 2.3% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | 3.47× | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
RAL
| Industrial Manufacturing | $111.1M | 21% |
| Defense And Space | $93.6M | 18% |
| Diversified Electronics | $91.0M | 17% |
| Test And Measurement | $76.8M | 15% |
| Communications | $60.7M | 11% |
| Semiconductors | $51.4M | 10% |
| Other Direct End Markets | $44.4M | 8% |
